TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05189925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp91 Grans
Description: Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
Study: NCT04811716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered Sub-cutaneous (SC) per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered Sub-cutaneous (SC) per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per protocol
Study: NCT05276973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT06636357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% N2O plus 50% O2
Description: Inhalation of 50% N2O plus 50% O2 for 45 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (O2)
Description: 50% O2 plus 50% air for 45 min
Study: NCT06263673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily, oral
Study: NCT05787587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE-161
Description: Oral Medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion
Study: NCT06230510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduction of Milk Type
Description: Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduction of Milk Type
Description: Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Nutrition Counseling
Description: Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Nutrition Counseling
Description: Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
Study: NCT06263673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
Study: NCT05564377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study: NCT05247957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK cells
Description: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
Study: NCT05901675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Management Program
Description: The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Management Program
Description: The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-stroke Optimization of Walking using Explosive Resistance
Description: POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
Study: NCT06220864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV1521
Description: SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV1521
Description: SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Study: NCT05031338

Intervention type: DEVICE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.

Intervention type: DEVICE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.

Intervention type: PROCEDURE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.

Intervention type: PROCEDURE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
Study: NCT05315674

Intervention type: DIAGNOSTIC_TEST
Intervention: Frequent assessment of biomarker panel
Description: During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Frequent assessment of biomarker panel
Description: During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
Study: NCT06388096

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pattern Electroretinogram
Description: Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pattern Electroretinogram
Description: Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
Study: NCT05564377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study: NCT04990063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive TKC transfer therapy
Description: TKC: co-cultured autologous NK cells and γδT cells
Study: NCT05486325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endolumik Gastric Calibration Tube (EGCT)
Description: Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia.
Study: NCT06156657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcostal TAP block
Description: Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
Study: NCT05979220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib combined with Letrozole
Description: A multicenter, single arm, prospective Phase II clinical study
Study: NCT05723731

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS
Description: Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Laxative Agent
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laxative Agent
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
Study: NCT03924063

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemiverse
Description: Implantation of the hemiverse shoulderprothesis
Study: NCT04954274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclic peptide Fertiline
Description: Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide.
Study: NCT05557604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl
Description: STAD androgen deprivation
Study: NCT05564377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06064669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Study: NCT05213312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5Fluorouracil
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagectomy (minimally invasive)
Description: 4-6 weeks after neoadjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy (minimally invasive)
Description: 4-6 weeks after neoadjuvant therapy.
Study: NCT05655559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnare
Description: Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnare
Description: Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Muscle Oxygen Monitor
Description: Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Muscle Oxygen Monitor
Description: Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
Study: NCT04915118

Intervention type: OTHER
Intervention: Decompensation event
Description: NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
Study: NCT04727632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoroestradiol (FES) PET/CT
Description: \[18F\]Fluoroestradiol (FES) PET/CT
Study: NCT04233398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Echopulse (HIFU ablation)
Description: High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ